Spots Global Cancer Trial Database for monotherapy
Every month we try and update this database with for monotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC) | NCT00351949 | Stage IV Renal ... | IMP321 | 18 Years - | Immutep S.A.S. | |
| Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma | NCT02401542 | Locally Advance... Urinary Bladder... Urological Dise... | Vofatamab Docetaxel Placebo | 18 Years - | Rainier Therapeutics | |
| Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) | NCT04621188 | Non Small Cell ... | Lorlatinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Study of ART0380 in Patients With Biologically Selected Solid Tumors | NCT05798611 | Advanced Solid ... Recurrent Endom... Metastatic Canc... | ART0380 | 18 Years - | Artios Pharma Ltd | |
| HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer | NCT03424694 | Prostate Cancer | HDR brachythera... | 18 Years - 85 Years | CR-CSSS Champlain-Charles-Le Moyne | |
| Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy | NCT02403869 | Breast Neoplasm... | 18 Years - | Celgene | ||
| A Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer | NCT01890096 | Carcinoma of th... | HDR 2 Fraction HDR 1 Fraction | 18 Years - | Sunnybrook Health Sciences Centre | |
| Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors | NCT04669899 | Cancer | JTX-8064 pimivalimab | 18 Years - | Jounce Therapeutics, Inc. | |
| A Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer | NCT01890096 | Carcinoma of th... | HDR 2 Fraction HDR 1 Fraction | 18 Years - | Sunnybrook Health Sciences Centre | |
| NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers | NCT04808531 | Cancer Related ... | NanaBis™ Oxycodone CR Placebo Spray Placebo Tablet Oxycodone IR | 18 Years - 75 Years | Medlab Clinical | |
| HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer | NCT03424694 | Prostate Cancer | HDR brachythera... | 18 Years - 85 Years | CR-CSSS Champlain-Charles-Le Moyne | |
| Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | NCT04943627 | Advanced Cancer Metastatic Cerv... | Balstilimab (BA... Topotecan Vinorelbine Gemcitabine Irinotecan Pemetrexed | 18 Years - | Agenus Inc. | |
| A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | NCT03693300 | Non-small Cell ... | Durvalumab | 18 Years - 130 Years | AstraZeneca | |
| Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors | NCT04669899 | Cancer | JTX-8064 pimivalimab | 18 Years - | Jounce Therapeutics, Inc. | |
| CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients | NCT00526643 | Non-Small Cell ... | gemcitabine cisplatin | 18 Years - 70 Years | National Cancer Institute, Naples | |
| Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer | NCT02077335 | Prostate Cancer | HDR brachythera... | 18 Years - | CSSS de Gatineau | |
| A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours | NCT05537051 | Advanced Solid ... | PM1021, PM8001 | 18 Years - 75 Years | Biotheus Inc. | |
| GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer | NCT01397877 | Endometrial Can... | BKM120 | 18 Years - | ARCAGY/ GINECO GROUP | |
| IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC) | NCT00351949 | Stage IV Renal ... | IMP321 | 18 Years - | Immutep S.A.S. | |
| Study of ART0380 in Patients With Biologically Selected Solid Tumors | NCT05798611 | Advanced Solid ... Recurrent Endom... Metastatic Canc... | ART0380 | 18 Years - | Artios Pharma Ltd | |
| A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors | NCT05025085 | Advanced Cancer | AGEN1777 a PD-1 inhibito... | 18 Years - | Bristol-Myers Squibb | |
| CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients | NCT00526643 | Non-Small Cell ... | gemcitabine cisplatin | 18 Years - 70 Years | National Cancer Institute, Naples | |
| Study of AGEN1571 in Participants With Advanced Solid Tumors | NCT05377528 | Advanced Solid ... | AGEN1571 Balstilimab Botensilimab | 18 Years - | Agenus Inc. | |
| Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). | NCT06159166 | NF1 Cutaneous Neuro... Monotherapy | Mirdametinib | 18 Years - | Johns Hopkins University | |
| Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions | NCT05622071 | Hepatocellular ... | Tislelizumab | 18 Years - | UNICANCER | |
| Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 | NCT03356223 | Head and Neck C... Advanced Cancer Metastatic Canc... | Abemaciclib | 18 Years - | Centre Leon Berard | |
| Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer | NCT04111705 | Non Small Cell ... | Lorlatinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg | NCT00919477 | Prostate Cancer | - | AstraZeneca | ||
| Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg | NCT00919477 | Prostate Cancer | - | AstraZeneca | ||
| Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | NCT04987203 | Renal Cell Carc... | Tivozanib Nivolumab | 18 Years - 130 Years | AVEO Pharmaceuticals, Inc. | |
| PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | NCT03013491 | Solid Tumor Lymphoma | CX-072 ipilimumab vemurafenib | 18 Years - | CytomX Therapeutics | |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | NCT03860272 | Advanced Cancer Angiosarcoma Colorectal Canc... Endometrial Can... Fibrolamellar C... Non-small-cell ... Ovarian Cancer Prostate Cancer | Botensilimab Balstilimab | 18 Years - | Agenus Inc. | |
| Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884) | NCT05572970 | Cancer | Balstilimab Zalifrelimab | 18 Years - | Agenus Inc. | |
| Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer | NCT02077335 | Prostate Cancer | HDR brachythera... | 18 Years - | CSSS de Gatineau | |
| Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer | NCT04121676 | Advanced Cancer | AGEN2373 Botensilimab | 18 Years - | Agenus Inc. | |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | NCT03821935 | Advanced Solid ... | Livmoniplimab Budigalimab | 18 Years - | AbbVie | |
| Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy | NCT02403869 | Breast Neoplasm... | 18 Years - | Celgene | ||
| Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | NCT04987203 | Renal Cell Carc... | Tivozanib Nivolumab | 18 Years - 130 Years | AVEO Pharmaceuticals, Inc. | |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | NCT03821935 | Advanced Solid ... | Livmoniplimab Budigalimab | 18 Years - | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
